Antineoplaston Therapy in Treating Patients With Metastatic or Unresectable Colon Cancer

PHASE2TerminatedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

April 10, 1996

Primary Completion Date

May 11, 2003

Study Completion Date

May 11, 2003

Conditions
Colon Cancer
Interventions
DRUG

antineoplaston A10, antineoplaston AS2-1 (ANP)

"Patients with metastatic or unresectable Colon Cancer will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."

Trial Locations (1)

77055-6330

Burzynski Clinic, Houston

Sponsors
All Listed Sponsors
lead

Burzynski Research Institute

OTHER